"Benzamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BENZOIC ACID amides.
| Descriptor ID |
D001549
|
| MeSH Number(s) |
D02.065.277 D02.241.223.100.100 D02.455.426.559.389.127.085
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamides".
Below are MeSH descriptors whose meaning is more specific than "Benzamides".
This graph shows the total number of publications written about "Benzamides" by people in this website by year, and whether "Benzamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 5 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 4 | 6 |
| 2011 | 2 | 2 | 4 |
| 2012 | 4 | 0 | 4 |
| 2013 | 4 | 2 | 6 |
| 2014 | 2 | 6 | 8 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 4 | 5 |
| 2017 | 3 | 1 | 4 |
| 2018 | 3 | 3 | 6 |
| 2019 | 2 | 4 | 6 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 6 | 8 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 1 | 2 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzamides" by people in Profiles.
-
Simultaneous Presentation of Cutaneous Waldenstr?m Macroglobulinemia and Acalabrutinib-Related Toxicity. Am J Dermatopathol. 2025 Oct 01; 47(10):786-789.
-
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study. Oncologist. 2025 Jul 04; 30(7).
-
Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor-Positive Triple-Negative Breast Cancer by Inhibiting c-MYC-mediated Tumorigenesis. Mol Cancer Ther. 2025 Jun 04; 24(6):870-883.
-
Calcium-Sensing Receptor as a Novel Target for the Treatment of Idiopathic Pulmonary Fibrosis. Biomolecules. 2025 Apr 01; 15(4).
-
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 02; 220:115308.
-
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med. 2024 Dec; 13(24):e70226.
-
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer. 2024 Oct 30; 12(10).
-
GVHD targets organoid-forming bile duct stem cells in a TGF-?-dependent manner. Blood. 2024 08 22; 144(8):904-913.
-
Momelotinib for the treatment of myelofibrosis. Blood. 2024 08 15; 144(7):708-713.
-
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM. Future Oncol. 2024; 20(30):2259-2270.